TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today ...

Forma Life Sciences, Inc. today announced its launch as an independent, operator-owned contract development and manufacturing ...

Axcend and MassTech, Inc. announced that Axcend will offer the MassTech MTE30 as part of a combined liquid ...

Seasoned biopharma executive brings more than 25 years of business development and strategic partnership experience to ...

Emerging from stealth, RecovryAI introduces AI-powered, physician-prescribed Virtual Care Assistants for post-operative recoverySAN FRANCISCO--(BUSINESS WIRE)--RecovryAI today announced that the U.S.

Point-of-care testing refers to diagnostic procedures conducted near the patient or at the site of care, outside of ...

The Global Point-of-Care (POC) Diagnostics Market is projected to expand at a CAGR of 11% through 2028. Growth is being fueled by the rising burden of infectious diseases, increasing demand for rapid ...

Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast period. This rapid expansion is primarily fueled by the rising prevalence of ...

The global weight management market is projected to grow at a rate of 9-10% by 2029. This expansion is driven by several key ...

Phase 2 third cohort (28 days, 15 mg) generally safe and well toleratedARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026Cash runway extended into Q2 2028Investor ...

The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s ...